Low Blood Sugar on Insulin: What Could Be Causing It

How Common Is Hypoglycemia in People Taking Insulin?

Hypoglycemia is the most frequent adverse event associated with insulin therapy and the primary barrier to achieving tight glycemic targets. The real-world burden is substantially higher than clinical trial estimates suggest, because many episodes go unreported or unrecognized.

The landmark HAT (Hypoglycaemia Assessment Tool) study surveyed over 27,500 insulin-treated patients across 24 countries and found that self-reported hypoglycemia rates were 3 to 5 times higher than rates documented in medical records. Among type 2 diabetes patients on insulin, the study estimated 19.3 symptomatic episodes per patient per year. Type 1 diabetes patients fared worse, reporting 73.3 episodes per year. These figures confirm that mild, non-severe episodes are routine rather than exceptional.

Severe hypoglycemia carries distinct risks. In the ACCORD trial (N=10,251), the intensive-therapy group experienced severe hypoglycemia at a rate of 3.14% per year, and participants who had at least one severe episode showed higher all-cause mortality compared with those who did not [1]. The ADA 2024 Standards of Care classify glucose <54 mg/dL as Level 2 (clinically significant) hypoglycemia and glucose <70 mg/dL as Level 1 (alert value), establishing a two-tier system that guides clinical decision-making [2].

The economic impact compounds the clinical burden. A 2020 analysis in Diabetes Care estimated that non-severe hypoglycemia episodes cost $11 to $17 each in lost productivity, while a single severe episode requiring emergency care averaged $1,161 [3].

The Six Most Common Causes of Low Blood Sugar on Insulin

Pinpointing the trigger for a hypoglycemic episode requires evaluating several overlapping factors. Most cases trace back to one or more of these six causes.

Insulin-to-carbohydrate mismatch. This is the single most common cause. Taking a meal-time bolus without eating enough carbohydrate, or miscounting carbohydrates by as few as 10 to 15 grams, can drop blood glucose below 70 mg/dL within 60 to 90 minutes. The Endocrine Society's 2009 clinical practice guideline on hypoglycemia management identifies this mismatch as the primary modifiable risk factor and recommends structured carbohydrate-counting education as a first-line preventive intervention [4].

Excess insulin dosing. Stacking correction doses, using an outdated insulin-to-carbohydrate ratio, or injecting into a site with faster absorption (such as exercised muscle or areas with lipohypertrophy) can all produce relative overinsulinization. A fixed-dose regimen that does not account for day-to-day variability in activity or food intake amplifies this risk.

Physical activity. Exercise increases insulin-independent glucose uptake in skeletal muscle and enhances insulin sensitivity for 24 to 48 hours afterward. The ADA's position statement on physical activity notes that moderate aerobic exercise can reduce blood glucose by 40 to 100 mg/dL per hour, depending on circulating insulin levels and fitness [5]. Late-onset post-exercise hypoglycemia, occurring 6 to 15 hours after activity, catches many patients off guard.

Declining kidney function. The kidneys clear approximately 30% to 80% of circulating insulin. As the glomerular filtration rate falls below 45 mL/min, insulin half-life extends, and doses that were previously stable begin to produce hypoglycemia. A retrospective analysis published in Kidney International found that patients with stage 3b to 5 CKD had a 2.2-fold higher rate of severe hypoglycemia compared with patients whose GFR exceeded 60 mL/min [6].

Alcohol consumption. Ethanol inhibits hepatic gluconeogenesis for as long as it is being metabolized. Two standard drinks can suppress glucose output for 12 to 18 hours. The effect is additive with exogenous insulin, making post-drinking nocturnal hypoglycemia a well-documented phenomenon. The NICE guideline NG17 explicitly warns insulin-treated patients to consume carbohydrate alongside alcohol and to monitor glucose before sleep [7].

Impaired counterregulatory response. After repeated hypoglycemic episodes, the glucagon and epinephrine responses that normally correct low glucose become blunted. This phenomenon, called hypoglycemia-associated autonomic failure (HAAF), creates a vicious cycle: each unrecognized episode makes the next one more likely and more severe.

Hypoglycemia Unawareness: The Hidden Amplifier

Roughly 25% of people with type 1 diabetes and 10% of insulin-treated type 2 diabetes patients develop impaired awareness of hypoglycemia (IAH). They no longer feel the adrenergic warning signs (tremor, palpitations, sweating) that typically precede neuroglycopenic symptoms like confusion or seizure.

Dr. Philip Cryer, whose research at Washington University defined much of our understanding of counterregulatory failure, described the clinical consequence directly: "Hypoglycemia unawareness and defective glucose counterregulation are the components of HAAF that make iatrogenic hypoglycemia the limiting factor in the glycemic management of diabetes" [8]. This observation, published across multiple papers in the Journal of Clinical Investigation, shifted the field's approach from simply lowering A1C to balancing A1C targets against hypoglycemia risk.

The Clarke Hypoglycemia Awareness Questionnaire is a validated 8-item tool clinicians use to screen for IAH [9]. A score of 4 or higher (termed "reduced awareness") identifies patients who should receive structured hypoglycemia avoidance programs. Strict avoidance of all blood glucose values below 70 mg/dL for 2 to 3 weeks can partially restore awareness in many patients, a process sometimes called "hypoglycemia holiday." The ADA Standards of Care recommend raising glucose targets for these patients and considering continuous glucose monitoring (CGM) with predictive low-glucose alerts [2].

The Gold score and the Pedersen-Bjergaard method offer alternative screening tools. Clinical practice favors the Clarke questionnaire for its broader validation, but all three instruments outperform a single yes/no question about awareness.

How Is Low Blood Sugar on Insulin Diagnosed?

The Whipple triad remains the diagnostic foundation: symptoms consistent with hypoglycemia, a documented low plasma glucose at the time of symptoms, and resolution of symptoms when glucose is restored. For insulin-treated patients, confirmation usually comes from a glucometer reading or CGM trace.

Laboratory evaluation beyond point-of-care glucose matters when hypoglycemia is unexpectedly frequent or severe. Checking a basic metabolic panel and estimated GFR rules out renal impairment. Thyroid function testing excludes hypothyroidism, which slows insulin clearance modestly. Cortisol and ACTH levels screen for adrenal insufficiency, a condition with particular relevance in patients on chronic glucocorticoids who are being tapered. Celiac screening (tissue transglutaminase IgA) is appropriate in type 1 diabetes patients with unexplained hypoglycemia and weight loss, given the 5% to 8% celiac disease co-prevalence in this group [10].

CGM data provides the richest diagnostic information. Time below range (TBR, defined as glucose <70 mg/dL) should ideally remain under 4% of readings per 24 hours, per the international consensus on CGM targets published in Diabetes Care [11]. A TBR exceeding 4% signals the need for regimen adjustment. The ambulatory glucose profile (AGP) report, now standardized across CGM platforms, visualizes hypoglycemia patterns by time of day and makes it straightforward to identify overnight lows, post-exercise dips, or pre-meal nadirs.

The Endocrine Society guideline recommends documenting the "hypoglycemia context" for every episode: timing relative to meals, recent exercise, alcohol intake, injection site, and insulin dose [4]. A structured hypoglycemia diary kept for two weeks often reveals the pattern faster than laboratory workup alone.

Nocturnal Hypoglycemia: Why Overnight Lows Demand Special Attention

Low blood sugar during sleep is both common and dangerous. The ASPIRE In-Home trial (N=247) demonstrated that sensor-augmented pump therapy with automatic low-glucose suspend reduced nocturnal hypoglycemia events by 31.8% compared with sensor-augmented pump therapy alone, without increasing A1C [12]. This trial was among the first to prove that automated insulin delivery could meaningfully reduce overnight risk.

Nocturnal episodes are more likely to become severe because sleep suppresses the symptoms that would normally wake a person and prompt treatment. Contributing factors include residual activity of intermediate- or long-acting insulin peaking during the early morning hours, physical activity earlier in the day increasing overnight insulin sensitivity, and evening alcohol consumption impairing hepatic glucose output. The Somogyi effect (rebound hyperglycemia after nocturnal hypoglycemia) was once widely taught but has been challenged by CGM data showing that most fasting hyperglycemia in insulin-treated patients reflects the dawn phenomenon rather than a post-hypoglycemic rebound.

The ADA Technology in Diabetes Consensus Report endorses CGM with predictive low-glucose alerts for all patients with recurrent nocturnal hypoglycemia [13]. For patients not using CGM, checking glucose at 3 a.m. for 3 to 5 consecutive nights can reveal a pattern. A bedtime snack containing 15 to 30 grams of complex carbohydrate with protein (such as peanut butter on whole-grain crackers) remains a practical, low-cost measure.

Treatment: What to Do During a Low Blood Sugar Episode

Immediate management follows the "Rule of 15." Consume 15 to 20 grams of fast-acting glucose. Wait 15 minutes. Recheck. Repeat if glucose remains below 70 mg/dL.

Suitable fast-acting glucose sources include 4 glucose tablets (4 grams each), 4 ounces of juice or regular soda, or 1 tablespoon of honey. Chocolate, cookies, and other high-fat foods delay glucose absorption and are poor choices for acute treatment. The ADA notes that complex carbohydrates or mixed meals should follow the initial correction to prevent recurrence, particularly when the next scheduled meal is more than an hour away [2].

Severe hypoglycemia (inability to self-treat) requires glucagon. The FDA approved nasal glucagon (Baqsimi) in 2019 specifically because reconstituting traditional glucagon kits was error-prone for caregivers under stress [14]. Baqsimi delivers 3 mg of dry nasal glucagon powder in a single actuation. No priming, no mixing, no injection. The 2020 approval of dasiglucagon (Zegalogue), a ready-to-inject liquid glucagon that remains stable at room temperature, offered another advance in real-world usability.

The Endocrine Society guideline recommends that every insulin-treated patient have an unexpired glucagon formulation accessible at home and at work, and that at least one household member or close contact receive instruction on its use [4]. Yet surveys consistently show that only 30% to 40% of insulin-treated patients have a current glucagon prescription.

Dr. Elizabeth Seaquist, past president of the American Diabetes Association, stated in a 2022 ADA Presidential Address: "We must treat access to glucagon with the same urgency we treat access to epinephrine in anaphylaxis. Every person on insulin deserves a rescue plan" [15].

Prevention: Adjusting the Regimen to Reduce Hypoglycemia Risk

Prevention is a regimen problem, not a willpower problem. Systematic changes to insulin type, timing, and dosing structure reduce hypoglycemia rates more reliably than patient education alone.

Switching basal insulin. Second-generation basal analogs produce fewer nocturnal lows. The SWITCH 2 trial (N=721) randomized insulin-treated type 2 diabetes patients to degludec versus glargine U100 and found a 51% reduction in nocturnal confirmed hypoglycemia with degludec during the maintenance period [16]. Glargine U300 (Toujeo) also shows lower nocturnal hypoglycemia rates versus glargine U100 in the EDITION trial program [17].

CGM-guided dose titration. The DIAMOND trial (N=158) demonstrated that CGM use in multiple-daily-injection patients reduced time below 70 mg/dL from a median of 80 minutes/day to 43 minutes/day (a 46% reduction) over 24 weeks [18]. Ambulatory glucose profiles let clinicians and patients spot patterns of hypoglycemia that A1C alone cannot detect.

Structured education. Programs like DAFNE (Dose Adjustment for Normal Eating) have shown a 60% reduction in severe hypoglycemia episodes in type 1 diabetes patients over 12 months [19]. Carbohydrate counting, insulin dose adjustment around exercise, and alcohol management form the curriculum's core modules.

Automated insulin delivery (AID). Hybrid closed-loop systems adjust basal delivery in real time and suspend insulin when predicted glucose is falling. The Control-IQ key trial (N=168) showed time below 70 mg/dL dropped to 1.58% with AID versus 2.76% with sensor-augmented pump therapy [20]. For patients eligible for pump therapy, AID represents the most effective single intervention against hypoglycemia.

Medication review. Sulfonylureas and meglitinides add hypoglycemia risk on top of insulin. Discontinuing or reducing these agents when insulin is titrated upward is a straightforward but often overlooked step. The ADA/EASD 2022 consensus explicitly recommends deprescribing sulfonylureas when basal insulin is added [21].

When to Seek Emergency Care

Not every low requires the emergency department. But certain situations do.

Glucose below 54 mg/dL that does not rise above 70 after two rounds of the Rule of 15 warrants emergency evaluation. Any episode involving loss of consciousness, seizure, or inability to swallow calls for immediate glucagon administration and EMS activation. Recurrent severe hypoglycemia (two or more episodes requiring third-party assistance within 12 months) should trigger an urgent referral to endocrinology for regimen overhaul, hypoglycemia awareness assessment, and CGM initiation if not already in place.

The ADA Standards of Care note that severe hypoglycemia in elderly patients (age 75+) carries particularly high morbidity from falls, fractures, and cardiac arrhythmias, and recommend A1C targets of <8.0% (rather than <7.0%) in this population to reduce the risk [2].